The drug that is being followed with a telescope is Merck & Co., Inc (NYSE:MRK)'s BACE inhibitor. This very recently began its Phase-II/III study with patients suffering from mild-to-moderate Alzheimer's disease.
3 Drug Launches You Need to Know in 2013: Pfizer, NPS Pharma, Ariad The Food and Drug Administration (FDA) made a groundbreaking policy change last year that is having a large impact on the biotech industry and creating a big opportunity for investors ...
A classic example is that of the 2011 acquisition of Inspire by Merck & Co., Inc. (NYSE:MRK). $430 million was considered a great offer - at $5 a share, it represented a 26% premium to Inspire's share price at that time.
Merck & Co. is cutting jobs and stripping a layer of senior management from its research-and-development arm, as its new chief seeks to turnaround a unit he said is marked by "the complexity of our organizational design.